{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:49:39Z","timestamp":1792136979635,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01051-6","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:24:04Z","timestamp":1792135444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Health Care Resource Utilization, Adherence, and Persistence Following Subcutaneous IgPro20 Initiation Among US Patients with Chronic Inflammatory Demyelinating Polyneuropathy"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-8285","authenticated-orcid":false,"given":"Batyrkhan","family":"Kuatov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicheng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphonse","family":"Hubsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Undreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisara","family":"Chansakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Dabrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"1","key":"1051_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","volume":"73","author":"RS Laughlin","year":"2009","unstructured":"Laughlin RS, Dyck PJ, Melton LJ, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73(1):39\u201345.","journal-title":"Neurology"},{"issue":"6","key":"1051_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/1756285612457215","volume":"5","author":"KC Gorson","year":"2012","unstructured":"Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord. 2012;5(6):359\u201373.","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"1051_CR3","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1111\/ene.14959","volume":"28","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, Doorn PA, Hadden RDM, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force\u2014second revision. Eur J Neurol. 2021;28(11):3556\u201383.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1051_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2018;17(1):35\u201346.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1051_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RAC Hughes","year":"2008","unstructured":"Hughes RAC, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136\u201344.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1051_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/mus.24554","volume":"51","author":"YA Rajabally","year":"2015","unstructured":"Rajabally YA. Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2015;51(5):657\u201361.","journal-title":"Muscle Nerve"},{"key":"1051_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64699-6","author":"L Gentile","year":"2020","unstructured":"Gentile L, Mazzeo AT, Russo M, Arimatea I, Vita G, Toscano A. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7\u00a0years. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-64699-6.","journal-title":"Sci Rep"},{"issue":"6","key":"1051_CR8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/mus.26669","volume":"60","author":"G Cirillo","year":"2019","unstructured":"Cirillo G, Todisco V, Ricciardi D, Tedeschi G. Clinical-neurophysiological correlations in chronic inflammatory demyelinating polyradiculoneuropathy patients treated with subcutaneous immunoglobulin. Muscle Nerve. 2019;60(6):662\u20137.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1051_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s40120-023-00478-5","volume":"12","author":"C Anderson-Smits","year":"2023","unstructured":"Anderson-Smits C, Ritchey ME, Huang Z, et al. Intravenous immunoglobulin treatment patterns and outcomes in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a US claims database analysis. Neurol Ther. 2023;12(4):1119\u201332.","journal-title":"Neurol Ther"},{"issue":"11","key":"1051_CR10","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1007\/s10072-024-07640-3","volume":"45","author":"A Ramzi","year":"2024","unstructured":"Ramzi A, Maya S, Balousha N, et al. Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): a comprehensive systematic review of clinical studies and meta-analysis. Neurol Sci. 2024;45(11):5213\u201330.","journal-title":"Neurol Sci"},{"issue":"8","key":"1051_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40263-019-00655-x","volume":"33","author":"YN Lamb","year":"2019","unstructured":"Lamb YN, Syed YY, Dhillon S. Immune globulin subcutaneous (Human) 20% (Hizentra\u00ae): a review in chronic inflammatory demyelinating polyneuropathy. CNS Drugs. 2019;33(8):831\u20138.","journal-title":"CNS Drugs"},{"issue":"8","key":"1051_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/psp4.12647","volume":"10","author":"MA Tortorici","year":"2021","unstructured":"Tortorici MA, Yuraszeck T, Cornblath D, et al. Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. CPT Pharmacomet Syst Pharmacol. 2021;10(8):839\u201350.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"9","key":"1051_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/jnnp-2019-320314","volume":"90","author":"HC Lehmann","year":"2019","unstructured":"Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2019;90(9):981\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1051_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ene.14056","volume":"27","author":"H-P Hartung","year":"2019","unstructured":"Hartung H-P, Mallick R, Bril V, et al. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. Eur J Neurol. 2019;27(1):196\u2013203.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1051_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40120-025-00848-1","volume":"15","author":"S Gingele","year":"2026","unstructured":"Gingele S, Saparilla Pietschmann AC, Jendretzky KF, et al. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: 12\u00a0months results from an observational study. Neurol Ther. 2026;15(1):165\u201377.","journal-title":"Neurol Ther"},{"key":"1051_CR16","doi-asserted-by":"publisher","unstructured":"Gingele S, Koch M, Saparilla AC, et al. Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions. Ther Adv Neurol Disord. 2021;14:17562864211009100. https:\/\/doi.org\/10.1177\/17562864211009100.","DOI":"10.1177\/17562864211009100"},{"issue":"2","key":"1051_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cen3.12816","volume":"16","author":"N Terasaka","year":"2025","unstructured":"Terasaka N, Mizushima T, Niwa Y, Akasaki T, Usui H. Real-world safety and treatment patterns of subcutaneous IgPro20 for chronic inflammatory demyelinating polyneuropathy: post-marketing surveillance in Japan. Clin Exp Neuroimmunol. 2025;16(2):108\u201317.","journal-title":"Clin Exp Neuroimmunol"},{"key":"1051_CR18","doi-asserted-by":"crossref","unstructured":"Sawyer C, Radu A, Hubsch A, Katkade V. Safety of decade plus use of IgPro20 in the real world: post-marketing pharmacovigilance report. Poster presented at: 2024 Immunoglobulin National Society (IgNS) 13th national conference; October 17\u201320, 2024; Washington, D.C., USA. Poster 115.","DOI":"10.1016\/j.anai.2024.08.073"},{"key":"1051_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70123","author":"JU Okonkwo","year":"2025","unstructured":"Okonkwo JU, Williams EK, Sadjadi R, et al. Validation of chronic inflammatory demyelinating polyradiculoneuropathy coding in US claims data. Pharmacoepidemiol Drug Saf. 2025. https:\/\/doi.org\/10.1002\/pds.70123.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1051_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-4733.2006.00139.x","volume":"10","author":"AM Peterson","year":"2007","unstructured":"Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3\u201312.","journal-title":"Value Health"},{"issue":"9","key":"1051_CR21","first-page":"1273","volume":"27","author":"J Mardan","year":"2021","unstructured":"Mardan J, Hussain MA, Allan M, Grech LB. Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression. J Manag Care Spec Pharm. 2021;27(9):1273\u201395.","journal-title":"J Manag Care Spec Pharm"},{"key":"1051_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CEOR.S130334","volume":"9","author":"J Burks","year":"2017","unstructured":"Burks J, Marshall T, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. Clinicoecon Outcomes Res. 2017;9:251\u201360.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"1051_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.329","volume":"99","author":"S Wang","year":"2016","unstructured":"Wang S, Verpillat P, Rassen J, Patrick A, Garry E, Bartels D. Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin Pharmacol Ther. 2016;99(3):325\u201332.","journal-title":"Clin Pharmacol Ther"},{"key":"1051_CR24","unstructured":"Zhou X, de Luise C, Prince P, Shen R, Luo K, Louder A, Gatto N. Replication of risk characterization in a cohort with women with advanced ER+\/HER2- breast cancer using a new analytic tool. Pharmacoepidemiol Drug Saf. 2019;28(Suppl 2), Abstract 129."},{"key":"1051_CR25","doi-asserted-by":"crossref","unstructured":"Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;2017(1):CD010369.","DOI":"10.1002\/14651858.CD010369.pub2"},{"key":"1051_CR26","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.amjmed.2019.12.021","volume":"133","author":"CW Gillespie","year":"2020","unstructured":"Gillespie CW, Morin PE, Tucker JM, et al. Medication adherence, health care utilization, and spending among privately insured adults with chronic conditions in the United States, 2010\u20132016. Am J Med. 2020;133:690\u2013704.e19.","journal-title":"Am J Med"},{"issue":"45","key":"1051_CR27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.15585\/mmwr.mm6645a2","volume":"66","author":"AB Neiman","year":"2017","unstructured":"Neiman AB, Ruppar T, Ho M, et al. Improving medication adherence for chronic disease management\u2014innovations and opportunities. MMWR Morb Mortal Wkly Rep. 2017;66(45):1248\u201351.","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01051-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01051-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:24:06Z","timestamp":1792135446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01051-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":27,"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01051-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Batyrkhan Kuatov, Shicheng Weng, Alphonse Hubsch, and Laurence Undreiner are current employees and shareholders of CSL. Aisara Chansakul, Ann Madsen, and Elizabeth C. Dabrowski are employees of Datavant.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data is statistically de-identified under the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule\u2019s Expert Determination method and managed according to Optum\u00ae customer data use agreements. Use of Optum\u00ae de-identified data for Research does not require an institutional review board (IRB) review or an ethical waiver. The Optum de-identified data does not contain patient identifiable information. As a result, use of the data should not be classified as \u201chuman subjects\u201d research. Data used for this research are commercially available in a deidentified format and can be accessed through a licensing agreement with Optum\u00ae. Terms of agreement are specific to each client.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}